According to Turkish media reports, Turkey began final Phase III trials of an experimental Chinese coronavirus vaccine on 16 September 2020, Reuters news agency reported on Wednesday.
This vaccine will be administered to 1,200 to 1,300 health workers over 10 days and a second dose will be given 14 days after the first, broadcasters CNN Turk and Haberturk reported, with the results of the trial sent the World Health Organisation (WHO).
The broadcasters added that the vaccine candidate will later be administered to volunteers with chronic diseases, with the aim of vaccinating 13,000 people.
According to Reuters, Turkey's health ministry did not comment on the reports, however, Health Minister Fahrettin Koca is due to hold a news conference later on 16 September.
Koca had announced that Phase III work had started on the Chinese vaccine candidate, as well as another developed by Pfizer. Russia's application to conduct Phase III trials in Turkey for its experimental vaccine was being evaluated and a decision would likely be made this week, he had said.
China launched a vaccine emergency use programme in July 2020, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and US-listed Sinovac Biotech. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Broadcaster Haberturk added that the vaccine candidate on trial in Turkey was developed by Sinovac.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA